Tingting Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tingting Liu has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Xu Wang
7 shared publicationsChengcai Xia
Department of Medicinal Chemistry, School of Pharmacy, State Key Laboratory of Advanced Drug Delivery and Release Systems, Shandong First Medical University, Jinan, Shandong, 250117, China
5 shared publicationsShubin Song
5 shared publicationsWenjie Liu
5 shared publicationsYuqi Gao
5 shared publicationsGaopan Dong
4 shared publications
Latest Publications
- 16 September 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 320
Novel far-red fluorescent theranostic probes for selective imaging and targeted therapy of BET proteins in breast cancer
- 16 September 2026
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 320
Novel far-red fluorescent theranostic probes for selective imaging and targeted therapy of BET proteins in breast cancer
- 21 February 2026
- Published by Elsevier in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
- Vol. 354, 127609
Novel active site -targeted fluorescent probes for real-time monitoring of CDK4/6 in tumor cells and tissues
- 21 February 2026
- Published by Elsevier in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
- Vol. 354, 127609
Novel active site -targeted fluorescent probes for real-time monitoring of CDK4/6 in tumor cells and tissues
- 22 September 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 301, 118180
Discovery of fluorescent theranostic molecular glues for real-time visualization and target degradation toward eEF2K
- 22 September 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 301, 118180
Discovery of fluorescent theranostic molecular glues for real-time visualization and target degradation toward eEF2K
- 19 June 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 296, 117886
Achieving dual-target fluorescent probes for tracing and inhibiting BRD4/PLK1 in tumor cells and tissues synchronously
- 19 June 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 296, 117886
Achieving dual-target fluorescent probes for tracing and inhibiting BRD4/PLK1 in tumor cells and tissues synchronously
- 12 December 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 283, 117151
Achieving theranostic probes targeting BRD3/BRD4 for imaging and therapy of tumor
- 12 December 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 283, 117151
Achieving theranostic probes targeting BRD3/BRD4 for imaging and therapy of tumor
- 23 October 2024
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 89 (21) , 16038-16042
Concise Synthesis and Biological Evaluation of the Pyrrolo[4,3,2-de]quinoline Core of the Lymphostin Family
The efficient synthesis of the pyrrolo[4,3,2-de]quinoline core of the lymphostin family (compound 1) has been accomplished in 7 steps and 18.6% overall yield, providing an efficient method for the total synthesis and structural modification of the lymphostin family. Compound 1 showed potent inhibitory activities against PI3K/mTOR in the nanomolar range and activity against human colorectal cancer cell lines comparable to that of oxaliplatin, which could be recognized as a novel lead compound for cancer therapy.
- 23 October 2024
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 89 (21) , 16038-16042
Concise Synthesis and Biological Evaluation of the Pyrrolo[4,3,2-de]quinoline Core of the Lymphostin Family
The efficient synthesis of the pyrrolo[4,3,2-de]quinoline core of the lymphostin family (compound 1) has been accomplished in 7 steps and 18.6% overall yield, providing an efficient method for the total synthesis and structural modification of the lymphostin family. Compound 1 showed potent inhibitory activities against PI3K/mTOR in the nanomolar range and activity against human colorectal cancer cell lines comparable to that of oxaliplatin, which could be recognized as a novel lead compound for cancer therapy.
- Open Access
- 16 July 2024
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 9, 100248
Single-cell transcriptomic analysis uncovers heterogeneity in the labial gland microenvironment of primary Sjögren's syndrome
- 16 July 2024
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 9, 100248
Open AccessSingle-cell transcriptomic analysis uncovers heterogeneity in the labial gland microenvironment of primary Sjögren's syndrome
- 29 May 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 257, 115478
Establishment of environment-sensitive probes targeting BRD3/BRD4 for imaging and therapy of tumor
- 29 May 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 257, 115478
Establishment of environment-sensitive probes targeting BRD3/BRD4 for imaging and therapy of tumor
- 13 December 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (24) , 16099-16127
Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment
The nuclear enzymes called poly(ADP-ribose)polymerases (PARPs) are known to catalyze the process of PARylation, which plays a vital role in various cellular functions. They have become important targets for the discovery of novel antitumor drugs since their inhibition can induce significant lethality in tumor cells. Therefore, researchers all over the world have been focusing on developing novel and potent PARP inhibitors for cancer therapy. Studies have shown that PARP inhibitors and other antitumor agents, such as EZH2 and EGFR inhibitors, play a synergistic role in cancer cells. The combined inhibition of PARP and the targets with synergistic effects may provide a rational strategy to improve the effectiveness of current anticancer regimens. In this Perspective, we sum up the recent advance of PARP-targeted agents, including single-target inhibitors/degraders and dual-target inhibitors/degraders, discuss the fundamental theory of developing these dual-target agents, and give insight into the corresponding structure-activity relationships of these agents.
- 13 December 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (24) , 16099-16127
Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment
The nuclear enzymes called poly(ADP-ribose)polymerases (PARPs) are known to catalyze the process of PARylation, which plays a vital role in various cellular functions. They have become important targets for the discovery of novel antitumor drugs since their inhibition can induce significant lethality in tumor cells. Therefore, researchers all over the world have been focusing on developing novel and potent PARP inhibitors for cancer therapy. Studies have shown that PARP inhibitors and other antitumor agents, such as EZH2 and EGFR inhibitors, play a synergistic role in cancer cells. The combined inhibition of PARP and the targets with synergistic effects may provide a rational strategy to improve the effectiveness of current anticancer regimens. In this Perspective, we sum up the recent advance of PARP-targeted agents, including single-target inhibitors/degraders and dual-target inhibitors/degraders, discuss the fundamental theory of developing these dual-target agents, and give insight into the corresponding structure-activity relationships of these agents.
- 18 November 2022
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 32 (1) , 99-108
Design, synthesis and anticancer activity studies of novel indole derivatives as Bcl-2/Mcl-1 dual inhibitors
- 18 November 2022
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 32 (1) , 99-108
Design, synthesis and anticancer activity studies of novel indole derivatives as Bcl-2/Mcl-1 dual inhibitors